Review Article
The Challenge of Applications of Probiotics in Gastrointestinal Diseases
Table 2
Effect of bacteriocins on gastrointestinal health.
| Bacteriocin | Class | Producing strain | Effect | References |
| Abp118 | II | L. salivarius UCC118 | Alleviate metabolic abnormalities associated with obesity | [39] | Pediocin PA-1 | II | P. acidilactici PAC1.0 | Reduce the intestinal colonization of VRE; inhibit the growth of DLD-1 and HT29 | [38, 49, 96] | Garvicin ML | II | L. garvieae DCC43 | Significantly increase the counts of total LAB and decrease the blood serum levels of triglycerides | [23] | Nisin | I | L. lactis | Regulate the intestinal immune; inhibit colorectal cancer in vitro | [43, 97, 98] | CBP22 | I | Clostridium butyricum ZJU-F1 | Prevention of LPS-induced gut barrier dysfunction by modulating the immune system | [42] | Plantaricin P1053 | I | L. plantarum PBS067 | Reduce proliferation of cancer-causing human intestinal cells | [47] | Reuterin | II | L. reuteri | Anticancer activity against HCT-116, SW480, RKO, and DLD-1 colorectal cancer cells | [45, 50] | Nisin A | I | L. lactis | Inhibit colorectal cancer cells LS180, SW48, HT29, and Caco-2 | [99] | Pediocin K2a2-3 | II | P. acidilactici K2a2-3 | Inhibit the proliferation of HT29 | [100, 101] | Bactofencin A | II | L. salivarius DPC6502 | Alter the proportions of several important gut bacteria, such as Fusobacterium, Bacteroides, and Bifidobacterium | [102] | Plantaricin EF | II | L. plantarum 163 | Ameliorate the effects of obesogenic diets; acute inflammatory bowel disease | [31, 44] | Gassericin A | V | L. gasseri LA39 | Affect the differentiation and development of adipocytes | [103] |
|
|